Zoetis Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Zoetis ha aumentado sus beneficios a una tasa media anual de 10.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 8.2% al año. La rentabilidad financiera de Zoetis es de 46.9%, y sus márgenes netos son de 27.4%.

Información clave

10.8%

Tasa de crecimiento de los beneficios

11.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	8.0%
Rentabilidad financiera	47.3%
Margen neto	27.4%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Zoetis Is An Awesome Dividend Growth Stock

Jan 17

It's A Great Time To Buy Zoetis Shares

Jan 10

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Jan 03

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Dec 29

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Zoetis raises quarterly dividend by 15.4% to $0.375/share

Dec 08

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Nov 20

Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth

Nov 08

Zoetis Q3 2022 Earnings Preview

Nov 02

Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?

Nov 02

Zoetis declares $0.325 dividend

Oct 13

A Rising Dollar May Mean Lower Zoetis Shares

Oct 07

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Sep 15

Zoetis cleared to acquire Jurox in Australia subject to divestiture

Sep 15

Zoetis acquires Scottish animal health digital tech business

Sep 05

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 21%?

Aug 19

Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar

Aug 12

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Zoetis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:ZTS Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	8,734	2,391	2,193	634
31 Dec 23	8,544	2,344	2,151	614
30 Sep 23	8,371	2,280	2,100	588
30 Jun 23	8,222	2,213	2,076	570
31 Mar 23	8,094	2,071	2,049	559
31 Dec 22	8,080	2,114	2,009	539
30 Sep 22	8,007	2,067	2,088	529
30 Jun 22	7,995	2,090	2,091	527
31 Mar 22	7,891	2,073	2,057	512
31 Dec 21	7,776	2,037	2,001	508
30 Sep 21	7,616	1,982	1,926	503
30 Jun 21	7,412	1,909	1,841	483
31 Mar 21	7,012	1,774	1,734	474
31 Dec 20	6,675	1,638	1,713	463
30 Sep 20	6,542	1,663	1,665	462
30 Jun 20	6,340	1,617	1,637	462
31 Mar 20	6,339	1,611	1,655	462
31 Dec 19	6,260	1,500	1,636	457
30 Sep 19	6,150	1,461	1,553	450
30 Jun 19	6,046	1,375	1,529	446
31 Mar 19	5,914	1,388	1,482	437
31 Dec 18	5,825	1,428	1,482	432
30 Sep 18	5,721	1,164	1,424	417
30 Jun 18	5,588	1,115	1,386	405
31 Mar 18	5,442	978	1,362	389
31 Dec 17	5,307	864	1,325	382
01 Oct 17	5,124	937	1,320	380
02 Jul 17	5,018	878	1,325	374
02 Apr 17	4,957	855	1,323	376
31 Dec 16	4,888	821	1,316	376
02 Oct 16	4,885	689	1,362	375
03 Jul 16	4,858	639	1,374	376
03 Apr 16	4,825	378	1,383	372
31 Dec 15	4,765	339	1,402	362
27 Sep 15	4,811	443	1,464	378
28 Jun 15	4,807	420	1,483	380
29 Mar 15	4,790	593	1,506	388
31 Dec 14	4,785	583	1,512	396
28 Sep 14	4,719	562	1,461	391
29 Jun 14	4,612	527	1,455	390
30 Mar 14	4,568	519	1,429	389
31 Dec 13	4,561	504	1,428	392
29 Sep 13	4,483	389	1,460	394
30 Jun 13	4,399	420	1,432	396

Ingresos de calidad: ZTS tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (27.4%) de ZTS son superiores a los del año pasado (26.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de ZTS han crecido un 10.8% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de ZTS en el último año (10.9%) supera su media de 5 años (10.8% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ZTS en el último año (10.9%) superó al de la industria Pharmaceuticals -6.8%.

Rentabilidad financiera

Alta ROE: Aunque la rentabilidad financiera (46.88%) de ZTS es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.

Zoetis Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Recent updates

Employee Advisor notifies of intention to sell stock

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

CEO & Director exercised options and sold US$1.7m worth of stock

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zoetis: My Dog Approves Of This Dividend Compounder

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

Zoetis: A Purrfect Addition To Your Portfolio

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

CEO & Director notifies of intention to sell stock

JAB Holdings B.V. acquired an unknown majority interest in Pumpkin Insurance Services Inc. from Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. Declares Dividend for Third Quarter of 2023, Payable on September 1, 2023

Zoetis Inc. Announces U.S. Food and Drug Administration Approves Librela™ (Bedinvetmab Injection) for Control of Pain Associated with Osteoarthritis in Dogs

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Key Executive exercised options and sold US$417k worth of stock

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Upcoming dividend of US$0.38 per share at 0.9% yield

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

CEO & Director exercised options and sold US$2.0m worth of stock

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Zoetis Inc. Declares Second Quarter 2023 Dividend, Payable on June 1, 2023

Zoetis Inc. Announces Termination of Glenn David as Executive Vice President and Group President, U.S. Operations

Zoetis Is An Awesome Dividend Growth Stock

Upcoming dividend of US$0.38 per share

Desglose de ingresos y gastos
Beta